A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma

Takahiro Horimatsu, Norisuke Nakayama, Toshikazu Moriwaki, Yoshinori Hirashima, Mikio Fujita, Masako Asayama, Ichiro Moriyama, Koji Nakashima, Eishi Baba, Hiroshi Kitamura, Takao Tamura, Ayumu Hosokawa, Kenichi Yoshimura, Manabu Muto

研究成果: ジャーナルへの寄稿記事

6 引用 (Scopus)

抄録

Background: Several studies have suggested that chemotherapy prolonged survival in patients with metastatic or recurrent small bowel adenocarcinoma (SBA); however, there is still no standard chemotherapy regimen. Here, we evaluated the efficacy and safety of a 5-fluorouracil (5-FU)/L-leucovorin (l-LV)/oxaliplatin (mFOLFOX6) protocol as a first-line therapy for patients with SBA. Patients and methods: This was a multicenter, single-arm, open-label phase II study. Eligibility criteria included histologically confirmed adenocarcinoma, age 20–80 years, and an Eastern Cooperative Oncology Group performance status (PS) of 0–2. The primary endpoint was 1-year progression-free survival (PFS). The secondary endpoints included overall response rate (ORR), overall survival (OS), overall PFS, and safety. Results: Between April 2010 and November 2012, 24 patients were enrolled from 12 institutions. The median age of the patients was 63 years (range 31–79) and there was a male/female ratio of 18/6. The number of PS 0/1 patients was 17/7 and locally advanced/metastatic disease was seen in 2/22 patients, respectively. The primary tumor site was the duodenum in 14 patients (58%) and jejunum in 10 patients (42%). The median follow-up time was 14.7 months (3.7–40.3). The 1-year PFS was 23.3%. The ORR was 9/20 (45%). The median PFS and OS times were 5.9 months (95% confidence interval [CI] 3.0–10.2) and 17.3 months (95% CI 11.7–19.0), respectively. Major grade 3/4 toxicities were neutropenia (38%), anemia/peripheral neuropathy (25%), and stenosis (17%). There were no treatment-related deaths. Conclusions: Although the primary endpoint was not met, mFOLFOX6 showed effective and good tolerance as a first-line treatment for SBA.

元の言語英語
ページ(範囲)905-912
ページ数8
ジャーナルInternational Journal of Clinical Oncology
22
発行部数5
DOI
出版物ステータス出版済み - 10 1 2017

Fingerprint

oxaliplatin
Leucovorin
Fluorouracil
Adenocarcinoma
Disease-Free Survival
Confidence Intervals
Safety
Drug Therapy
Survival

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hematology
  • Oncology

これを引用

A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma. / Horimatsu, Takahiro; Nakayama, Norisuke; Moriwaki, Toshikazu; Hirashima, Yoshinori; Fujita, Mikio; Asayama, Masako; Moriyama, Ichiro; Nakashima, Koji; Baba, Eishi; Kitamura, Hiroshi; Tamura, Takao; Hosokawa, Ayumu; Yoshimura, Kenichi; Muto, Manabu.

:: International Journal of Clinical Oncology, 巻 22, 番号 5, 01.10.2017, p. 905-912.

研究成果: ジャーナルへの寄稿記事

Horimatsu, T, Nakayama, N, Moriwaki, T, Hirashima, Y, Fujita, M, Asayama, M, Moriyama, I, Nakashima, K, Baba, E, Kitamura, H, Tamura, T, Hosokawa, A, Yoshimura, K & Muto, M 2017, 'A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma', International Journal of Clinical Oncology, 巻. 22, 番号 5, pp. 905-912. https://doi.org/10.1007/s10147-017-1138-6
Horimatsu, Takahiro ; Nakayama, Norisuke ; Moriwaki, Toshikazu ; Hirashima, Yoshinori ; Fujita, Mikio ; Asayama, Masako ; Moriyama, Ichiro ; Nakashima, Koji ; Baba, Eishi ; Kitamura, Hiroshi ; Tamura, Takao ; Hosokawa, Ayumu ; Yoshimura, Kenichi ; Muto, Manabu. / A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma. :: International Journal of Clinical Oncology. 2017 ; 巻 22, 番号 5. pp. 905-912.
@article{9f649fed90bc479bba7625b62ad55202,
title = "A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma",
abstract = "Background: Several studies have suggested that chemotherapy prolonged survival in patients with metastatic or recurrent small bowel adenocarcinoma (SBA); however, there is still no standard chemotherapy regimen. Here, we evaluated the efficacy and safety of a 5-fluorouracil (5-FU)/L-leucovorin (l-LV)/oxaliplatin (mFOLFOX6) protocol as a first-line therapy for patients with SBA. Patients and methods: This was a multicenter, single-arm, open-label phase II study. Eligibility criteria included histologically confirmed adenocarcinoma, age 20–80 years, and an Eastern Cooperative Oncology Group performance status (PS) of 0–2. The primary endpoint was 1-year progression-free survival (PFS). The secondary endpoints included overall response rate (ORR), overall survival (OS), overall PFS, and safety. Results: Between April 2010 and November 2012, 24 patients were enrolled from 12 institutions. The median age of the patients was 63 years (range 31–79) and there was a male/female ratio of 18/6. The number of PS 0/1 patients was 17/7 and locally advanced/metastatic disease was seen in 2/22 patients, respectively. The primary tumor site was the duodenum in 14 patients (58{\%}) and jejunum in 10 patients (42{\%}). The median follow-up time was 14.7 months (3.7–40.3). The 1-year PFS was 23.3{\%}. The ORR was 9/20 (45{\%}). The median PFS and OS times were 5.9 months (95{\%} confidence interval [CI] 3.0–10.2) and 17.3 months (95{\%} CI 11.7–19.0), respectively. Major grade 3/4 toxicities were neutropenia (38{\%}), anemia/peripheral neuropathy (25{\%}), and stenosis (17{\%}). There were no treatment-related deaths. Conclusions: Although the primary endpoint was not met, mFOLFOX6 showed effective and good tolerance as a first-line treatment for SBA.",
author = "Takahiro Horimatsu and Norisuke Nakayama and Toshikazu Moriwaki and Yoshinori Hirashima and Mikio Fujita and Masako Asayama and Ichiro Moriyama and Koji Nakashima and Eishi Baba and Hiroshi Kitamura and Takao Tamura and Ayumu Hosokawa and Kenichi Yoshimura and Manabu Muto",
year = "2017",
month = "10",
day = "1",
doi = "10.1007/s10147-017-1138-6",
language = "English",
volume = "22",
pages = "905--912",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma

AU - Horimatsu, Takahiro

AU - Nakayama, Norisuke

AU - Moriwaki, Toshikazu

AU - Hirashima, Yoshinori

AU - Fujita, Mikio

AU - Asayama, Masako

AU - Moriyama, Ichiro

AU - Nakashima, Koji

AU - Baba, Eishi

AU - Kitamura, Hiroshi

AU - Tamura, Takao

AU - Hosokawa, Ayumu

AU - Yoshimura, Kenichi

AU - Muto, Manabu

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background: Several studies have suggested that chemotherapy prolonged survival in patients with metastatic or recurrent small bowel adenocarcinoma (SBA); however, there is still no standard chemotherapy regimen. Here, we evaluated the efficacy and safety of a 5-fluorouracil (5-FU)/L-leucovorin (l-LV)/oxaliplatin (mFOLFOX6) protocol as a first-line therapy for patients with SBA. Patients and methods: This was a multicenter, single-arm, open-label phase II study. Eligibility criteria included histologically confirmed adenocarcinoma, age 20–80 years, and an Eastern Cooperative Oncology Group performance status (PS) of 0–2. The primary endpoint was 1-year progression-free survival (PFS). The secondary endpoints included overall response rate (ORR), overall survival (OS), overall PFS, and safety. Results: Between April 2010 and November 2012, 24 patients were enrolled from 12 institutions. The median age of the patients was 63 years (range 31–79) and there was a male/female ratio of 18/6. The number of PS 0/1 patients was 17/7 and locally advanced/metastatic disease was seen in 2/22 patients, respectively. The primary tumor site was the duodenum in 14 patients (58%) and jejunum in 10 patients (42%). The median follow-up time was 14.7 months (3.7–40.3). The 1-year PFS was 23.3%. The ORR was 9/20 (45%). The median PFS and OS times were 5.9 months (95% confidence interval [CI] 3.0–10.2) and 17.3 months (95% CI 11.7–19.0), respectively. Major grade 3/4 toxicities were neutropenia (38%), anemia/peripheral neuropathy (25%), and stenosis (17%). There were no treatment-related deaths. Conclusions: Although the primary endpoint was not met, mFOLFOX6 showed effective and good tolerance as a first-line treatment for SBA.

AB - Background: Several studies have suggested that chemotherapy prolonged survival in patients with metastatic or recurrent small bowel adenocarcinoma (SBA); however, there is still no standard chemotherapy regimen. Here, we evaluated the efficacy and safety of a 5-fluorouracil (5-FU)/L-leucovorin (l-LV)/oxaliplatin (mFOLFOX6) protocol as a first-line therapy for patients with SBA. Patients and methods: This was a multicenter, single-arm, open-label phase II study. Eligibility criteria included histologically confirmed adenocarcinoma, age 20–80 years, and an Eastern Cooperative Oncology Group performance status (PS) of 0–2. The primary endpoint was 1-year progression-free survival (PFS). The secondary endpoints included overall response rate (ORR), overall survival (OS), overall PFS, and safety. Results: Between April 2010 and November 2012, 24 patients were enrolled from 12 institutions. The median age of the patients was 63 years (range 31–79) and there was a male/female ratio of 18/6. The number of PS 0/1 patients was 17/7 and locally advanced/metastatic disease was seen in 2/22 patients, respectively. The primary tumor site was the duodenum in 14 patients (58%) and jejunum in 10 patients (42%). The median follow-up time was 14.7 months (3.7–40.3). The 1-year PFS was 23.3%. The ORR was 9/20 (45%). The median PFS and OS times were 5.9 months (95% confidence interval [CI] 3.0–10.2) and 17.3 months (95% CI 11.7–19.0), respectively. Major grade 3/4 toxicities were neutropenia (38%), anemia/peripheral neuropathy (25%), and stenosis (17%). There were no treatment-related deaths. Conclusions: Although the primary endpoint was not met, mFOLFOX6 showed effective and good tolerance as a first-line treatment for SBA.

UR - http://www.scopus.com/inward/record.url?scp=85019873495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019873495&partnerID=8YFLogxK

U2 - 10.1007/s10147-017-1138-6

DO - 10.1007/s10147-017-1138-6

M3 - Article

VL - 22

SP - 905

EP - 912

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 5

ER -